{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:08:48Z","timestamp":1791515328301,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"publisher","award":["TCVGH-1133701C"],"award-info":[{"award-number":["TCVGH-1133701C"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"publisher","award":["TCVGH-SCCS-SRD113005"],"award-info":[{"award-number":["TCVGH-SCCS-SRD113005"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"publisher","award":["TCVGH-NCNU1127903"],"award-info":[{"award-number":["TCVGH-NCNU1127903"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010101","name":"Taichung Veterans General Hospital","doi-asserted-by":"publisher","award":["TCVGH-NCNU1137903"],"award-info":[{"award-number":["TCVGH-NCNU1137903"]}],"id":[{"id":"10.13039\/501100010101","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 113-2320-B-260 -001 -MY3"],"award-info":[{"award-number":["NSTC 113-2320-B-260 -001 -MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-024-05920-2","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T03:59:05Z","timestamp":1733198345000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Doxorubicin synergizes bortezomib-induced multiple myeloma cell death by inhibiting aggresome formation and augmenting endoplasmic reticulum\/Golgi stress and apoptosis"],"prefix":"10.1186","volume":"22","author":[{"given":"Chang-Tze Ricky","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ting Amber","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Yin Nina","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo-Mei Maureen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Yu Bella","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Yun","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Jun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Rung","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9744-0368","authenticated-orcid":false,"given":"Chieh-Lin Jerry","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,3]]},"reference":[{"issue":"22","key":"5920_CR1","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.2174\/1568026611212220002","volume":"12","author":"CM Gomes","year":"2012","unstructured":"Gomes CM. Protein misfolding in disease and small molecule therapies. Curr Top Med Chem. 2012;12(22):2460\u20139.","journal-title":"Curr Top Med Chem"},{"issue":"2","key":"5920_CR2","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/sj.emboj.7601930","volume":"27","author":"KF Winklhofer","year":"2008","unstructured":"Winklhofer KF, Tatzelt J, Haass C. The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J. 2008;27(2):336\u201349.","journal-title":"EMBO J"},{"key":"5920_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.mito.2019.06.001","volume":"49","author":"LP Coyne","year":"2019","unstructured":"Coyne LP, Chen XJ. Consequences of inner mitochondrial membrane protein misfolding. Mitochondrion. 2019;49:46\u201355.","journal-title":"Mitochondrion"},{"issue":"9","key":"5920_CR4","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1016\/j.bbamem.2018.02.013","volume":"1860","author":"B Cheng","year":"2018","unstructured":"Cheng B, Li Y, Ma L, Wang Z, Petersen RB, Zheng L, et al. Interaction between amyloidogenic proteins and biomembranes in protein misfolding diseases: mechanisms, contributors, and therapy. Biochim Biophys Acta Biomembr. 2018;1860(9):1876\u201388.","journal-title":"Biochim Biophys Acta Biomembr"},{"issue":"1","key":"5920_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0086894","volume":"9","author":"G Liang","year":"2014","unstructured":"Liang G, Lian C, Huang D, Gao W, Liang A, Peng Y, et al. Endoplasmic reticulum stress-unfolding protein response-apoptosis cascade causes chondrodysplasia in a col2a1 pGly1170Ser mutated mouse model. PLoS ONE. 2014;9(1): e86894.","journal-title":"PLoS ONE"},{"key":"5920_CR6","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1146\/annurev-pharmtox-010919-023603","volume":"60","author":"LD Fricker","year":"2020","unstructured":"Fricker LD. Proteasome inhibitor drugs. Annu Rev Pharmacol Toxicol. 2020;60:457\u201376.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"6","key":"5920_CR7","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S0092-8674(03)00939-5","volume":"115","author":"Y Kawaguchi","year":"2003","unstructured":"Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell. 2003;115(6):727\u201338.","journal-title":"Cell"},{"issue":"2","key":"5920_CR8","doi-asserted-by":"publisher","first-page":"173","DOI":"10.4161\/pri.28123","volume":"8","author":"B Jia","year":"2014","unstructured":"Jia B, Wu Y, Zhou Y. 14-3-3 and aggresome formation: implications in neurodegenerative diseases. Prion. 2014;8(2):173\u20137.","journal-title":"Prion"},{"issue":"6","key":"5920_CR9","first-page":"1079","volume":"14","author":"Y Park","year":"2018","unstructured":"Park Y, Park J, Kim YK. Crosstalk between translation and the aggresome-autophagy pathway. Autophagy. 2018;14(6):1079\u201381.","journal-title":"Autophagy"},{"issue":"1","key":"5920_CR10","doi-asserted-by":"publisher","first-page":"8022","DOI":"10.1038\/s41598-017-07403-5","volume":"7","author":"M Nassar","year":"2017","unstructured":"Nassar M, Samaha H, Ghabriel M, Yehia M, Taha H, Salem S, et al. LC3A silencing hinders aggresome vimentin cage clearance in primary choroid plexus carcinoma. Sci Rep. 2017;7(1):8022.","journal-title":"Sci Rep"},{"issue":"24","key":"5920_CR11","doi-asserted-by":"publisher","first-page":"8567","DOI":"10.1073\/pnas.0503221102","volume":"102","author":"T Hideshima","year":"2005","unstructured":"Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA. 2005;102(24):8567\u201372.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"5920_CR12","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.3390\/ijms22031341","volume":"22","author":"SW Lee","year":"2021","unstructured":"Lee SW, Yeon SK, Kim GW, Lee DH, Jeon YH, Yoo J, et al. HDAC6-selective inhibitor overcomes bortezomib resistance in multiple myeloma. Int J Mol Sci. 2021;22(3):1341.","journal-title":"Int J Mol Sci"},{"issue":"10272","key":"5920_CR13","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397(10272):410\u201327.","journal-title":"Lancet"},{"issue":"14","key":"5920_CR14","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376(14):1311\u201320.","journal-title":"N Engl J Med"},{"issue":"4","key":"5920_CR15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0960-894X(98)00029-8","volume":"8","author":"J Adams","year":"1998","unstructured":"Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, Grenier L, et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett. 1998;8(4):333\u20138.","journal-title":"Bioorg Med Chem Lett"},{"issue":"5","key":"5920_CR16","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1517\/17425255.4.5.639","volume":"4","author":"E Terpos","year":"2008","unstructured":"Terpos E, Roussou M, Dimopoulos MA. Bortezomib in multiple myeloma. Expert Opin Drug Metab Toxicol. 2008;4(5):639\u201354.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"5920_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3390\/ph16010111","volume":"16","author":"G Kozalak","year":"2023","unstructured":"Kozalak G, Butun I, Toyran E, Kosar A. Review on bortezomib resistance in multiple myeloma and potential role of emerging technologies. Pharmaceuticals. 2023;16(1):111.","journal-title":"Pharmaceuticals"},{"issue":"7","key":"5920_CR18","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/nbt.1549","volume":"27","author":"J Lehar","year":"2009","unstructured":"Lehar J, Krueger AS, Avery W, Heilbut AM, Johansen LM, Price ER, et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol. 2009;27(7):659\u201366.","journal-title":"Nat Biotechnol"},{"issue":"2","key":"5920_CR19","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10529-015-1968-0","volume":"38","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Bai C, Lu D, Wu X, Gao L, Zhang W. Endoplasmic reticulum stress and autophagy participate in apoptosis induced by bortezomib in cervical cancer cells. Biotechnol Lett. 2016;38(2):357\u201365.","journal-title":"Biotechnol Lett"},{"issue":"10","key":"5920_CR20","doi-asserted-by":"publisher","first-page":"3869","DOI":"10.1007\/s11010-021-04187-1","volume":"476","author":"K Oh-Hashi","year":"2021","unstructured":"Oh-Hashi K, Hasegawa T, Mizutani Y, Takahashi K, Hirata Y. Elucidation of brefeldin A-induced ER and Golgi stress responses in Neuro2a cells. Mol Cell Biochem. 2021;476(10):3869\u201377.","journal-title":"Mol Cell Biochem"},{"issue":"10","key":"5920_CR21","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1016\/j.neurobiolaging.2011.11.014","volume":"33","author":"FJ Diaz-Corrales","year":"2012","unstructured":"Diaz-Corrales FJ, Miyazaki I, Asanuma M, Ruano D, Rios RM. Centrosomal aggregates and Golgi fragmentation disrupt vesicular trafficking of DAT. Neurobiol Aging. 2012;33(10):2462\u201377.","journal-title":"Neurobiol Aging"},{"issue":"23","key":"5920_CR22","doi-asserted-by":"publisher","first-page":"5896","DOI":"10.3390\/ijms20235896","volume":"20","author":"A Kishino","year":"2019","unstructured":"Kishino A, Hayashi K, Maeda M, Jike T, Hidai C, Nomura Y, et al. Caspase-8 regulates endoplasmic reticulum stress-induced necroptosis independent of the apoptosis pathway in auditory cells. Int J Mol Sci. 2019;20(23):5896.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"5920_CR23","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nchembio.2326","volume":"13","author":"J Li","year":"2017","unstructured":"Li J, Yakushi T, Parlati F, Mackinnon AL, Perez C, Ma Y, et al. Capzimin is a potent and specific inhibitor of proteasome isopeptidase Rpn11. Nat Chem Biol. 2017;13(5):486\u201393.","journal-title":"Nat Chem Biol"},{"issue":"3","key":"5920_CR24","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2174\/156800911794519770","volume":"11","author":"AD Schimmer","year":"2011","unstructured":"Schimmer AD. Clioquinol - a novel copper-dependent and independent proteasome inhibitor. Curr Cancer Drug Targets. 2011;11(3):325\u201331.","journal-title":"Curr Cancer Drug Targets"},{"issue":"14","key":"5920_CR25","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1002\/glia.21047","volume":"58","author":"SB Janen","year":"2010","unstructured":"Janen SB, Chaachouay H, Richter-Landsberg C. Autophagy is activated by proteasomal inhibition and involved in aggresome clearance in cultured astrocytes. Glia. 2010;58(14):1766\u201374.","journal-title":"Glia"},{"issue":"4","key":"5920_CR26","doi-asserted-by":"publisher","first-page":"659","DOI":"10.3390\/cells12040659","volume":"12","author":"M Kciuk","year":"2023","unstructured":"Kciuk M, Gielecinska A, Mujwar S, Kolat D, Kaluzinska-Kolat Z, Celik I, et al. Doxorubicin-an agent with multiple mechanisms of anticancer activity. Cells. 2023;12(4):659.","journal-title":"Cells"},{"issue":"6","key":"5920_CR27","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.molcel.2013.08.016","volume":"51","author":"R Hao","year":"2013","unstructured":"Hao R, Nanduri P, Rao Y, Panichelli RS, Ito A, Yoshida M, et al. Proteasomes activate aggresome disassembly and clearance by producing unanchored ubiquitin chains. Mol Cell. 2013;51(6):819\u201328.","journal-title":"Mol Cell"},{"issue":"5","key":"5920_CR28","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1083\/jcb.201708168","volume":"217","author":"Z Sha","year":"2018","unstructured":"Sha Z, Schnell HM, Ruoff K, Goldberg A. Rapid induction of p62 and GABARAPL1 upon proteasome inhibition promotes survival before autophagy activation. J Cell Biol. 2018;217(5):1757\u201376.","journal-title":"J Cell Biol"},{"issue":"5","key":"5920_CR29","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.semcdb.2011.12.006","volume":"23","author":"EK Fredrickson","year":"2012","unstructured":"Fredrickson EK, Gardner RG. Selective destruction of abnormal proteins by ubiquitin-mediated protein quality control degradation. Semin Cell Dev Biol. 2012;23(5):530\u20137.","journal-title":"Semin Cell Dev Biol"},{"issue":"16","key":"5920_CR30","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1182\/blood.2019000241","volume":"134","author":"L Rosinol","year":"2019","unstructured":"Rosinol L, Oriol A, Rios R, Sureda A, Blanchard MJ, Hernandez MT, et al. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma. Blood. 2019;134(16):1337\u201345.","journal-title":"Blood"},{"issue":"25","key":"5920_CR31","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","volume":"25","author":"RZ Orlowski","year":"2007","unstructured":"Orlowski RZ, Nagler A, Sonneveld P, Blade J, Hajek R, Spencer A, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol. 2007;25(25):3892\u2013901.","journal-title":"J Clin Oncol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05920-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-024-05920-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-05920-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T04:54:19Z","timestamp":1733201659000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-024-05920-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,3]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5920"],"URL":"https:\/\/doi.org\/10.1186\/s12967-024-05920-2","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,3]]},"assertion":[{"value":"14 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Chieh-Lin Jerry Teng received honorarium and consulting fees from Novartis, Roche, Pfizer, Takeda, Johnson and Johnson, Amgen, BMS Celgene, Kirin, TTY, and MSD. The other authors have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1095"}}